Kallmann syndrome in women: from genes to diagnosis and treatment
- PMID: 23368665
- DOI: 10.3109/09513590.2012.752459
Kallmann syndrome in women: from genes to diagnosis and treatment
Abstract
Kallmann syndrome (KS) can be characterized as genetic disorder marked by hypogonadotropic hypogonadism and anosmia. Franz Jozef Kallmann was the first who described this disease in 1944. He suggested, that this disease has hereditary background. At present, six genes are regarded as causal genes of KS. These genes can be listed in chronological order: KAL1, FGFR1, FGF8, CHD7, PROKR2 and PROK2. The sensitivity of molecular testing of KS is only about 30%. Diagnosis based on clinical findings is therefore such important. Cardinal features of patients with KS include hypogonadotropic hypogonadism and anosmia or hyposmia. Some non-reproductive, non-olfactory symptoms can also be present, depending on the genetic form of disease. Some patients with KS present midline cranial anomalies (cleft lip, cleft palate and imperfect fusion). Sometimes patients can also suffer from missing teeth (dental agenesis). Optic problems, such as colour blindness or optic atrophy also can occur in KS patients. Very characteristic symptom in KS patients is mirror movements of the upper limbs (imitation synkinesis for contralateral limbs). The type of treatment in women with KS depends on the goal of therapy. After the diagnosis of syndrome, the main goal of the treatment is to induce and maintain secondary sex characteristic (estrogen-progestin therapy). The further goal in some patients can be related to enable fertility (gonadotropin, gonadotropin-releasing hormone therapy).
Similar articles
-
The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al.Sex Dev. 2008;2(4-5):181-93. doi: 10.1159/000152034. Epub 2008 Nov 5. Sex Dev. 2008. PMID: 18987492 Review.
-
Genetic analysis in patients with Kallmann syndrome: coexistence of mutations in prokineticin receptor 2 and KAL1.J Androl. 2009 Jan-Feb;30(1):41-5. doi: 10.2164/jandrol.108.005314. Epub 2008 Aug 21. J Androl. 2009. PMID: 18723471
-
Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.J Clin Endocrinol Metab. 2013 May;98(5):E943-53. doi: 10.1210/jc.2012-4116. Epub 2013 Mar 26. J Clin Endocrinol Metab. 2013. PMID: 23533228 Free PMC article.
-
[Hypogonadotropic hypogonadism: new aspects in the regulation of hypothalamic-pituitary-gonadal axis].Ann Endocrinol (Paris). 2010 Sep;71 Suppl 1:S33-41. doi: 10.1016/S0003-4266(10)70005-6. Ann Endocrinol (Paris). 2010. PMID: 21237329 French.
-
[Molecular genetics of Kallmann syndrome: an update].Zhonghua Nan Ke Xue. 2011 Apr;17(4):361-5. Zhonghua Nan Ke Xue. 2011. PMID: 21548217 Review. Chinese.
Cited by
-
Olfactory Agenesis in Kallmann Syndrome (KS).J Clin Diagn Res. 2015 Apr;9(4):OJ01. doi: 10.7860/JCDR/2015/11761.5777. Epub 2015 Apr 1. J Clin Diagn Res. 2015. PMID: 26023587 Free PMC article. No abstract available.
-
Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease.Biol Sex Differ. 2019 Feb 4;10(1):7. doi: 10.1186/s13293-019-0223-0. Biol Sex Differ. 2019. PMID: 30717770 Free PMC article. Review.
-
Eight rare urinary disorders in a patient with Kallmann syndrome: A case report.Medicine (Baltimore). 2020 Oct 23;99(43):e22936. doi: 10.1097/MD.0000000000022936. Medicine (Baltimore). 2020. PMID: 33120852 Free PMC article.
-
Ataxia and focal dystonia in Kallmann syndrome.Clin Case Rep. 2015 Dec 28;4(2):182-5. doi: 10.1002/ccr3.420. eCollection 2016 Feb. Clin Case Rep. 2015. PMID: 26862419 Free PMC article.
-
Advances in Genetic Diagnosis of Kallmann Syndrome and Genetic Interruption.Reprod Sci. 2022 Jun;29(6):1697-1709. doi: 10.1007/s43032-021-00638-8. Epub 2021 Jul 6. Reprod Sci. 2022. PMID: 34231173 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous